Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies

Title	Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies
Authors	Ilya Pokataev, Mikhail Fedyanin, Elizaveta Polyanskaya, Anna Popova, Julia Agafonova, Sophia Menshikova, Alexey Tryakin, Alexey Rumyantsev, Sergei Tjulandin
Magazine	ESMO Open
Date	01/29/2020
DOI	10.1136/esmoopen-2019-000578
Introduction	This study aimed to assess the impact of homologous recombination deficiency (HRD) on the prognosis and effectiveness of platinum-based chemotherapy for pancreatic cancer patients. A detailed analysis was conducted by reviewing data from 4 meta-analysis studies and 16 systematic review studies. The findings indicate that patients with HRD showed improved overall survival with platinum-based chemotherapy, whereas those without HRD experienced longer survival without chemotherapy. The results support the potential benefits of platinum chemotherapy for HRD patients in both resected and metastatic pancreatic cancer, although further randomised trials are necessary for definitive conclusions.
Quote	Ilya Pokataev, Mikhail Fedyanin and Elizaveta Polyanskaya et al. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open. 2020. Vol. 5(1). DOI: 10.1136/esmoopen-2019-000578
Element	Platinum (Pt)
Industry	Pharmaceutical Industry